GLP-1s & Weight Loss
Route(s)
Subcutaneous
Typical dose
2.5mg to 5.0mg
Dosing window
Anytime
Receptor / target
Prohibitin
Properties
Not listed
Pre-mixed
No
Adipotide (FTPP)
← Back to Library
Protocol not independently verified Metabolic Proapoptotic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Compound Profile
Adipotide (FTPP) is reviewed here for weight loss, blood sugar, and appetite regulation.
Research Summary
Evidence Strength
Limited
Primary Evidence
Published literature searches and source-listed protocols
Research Focus
Weight loss, Blood sugar, Appetite regulation
Mechanism
Target context: Prohibitin
Long-Term Data
Limited or not established.
Current Consensus
Treat protocols as educational examples unless stronger sources are listed.
Route(s)
Subcutaneous
Typical dose
2.5mg to 5.0mg
Dosing window
Anytime
Receptor / target
Prohibitin
Properties
Not listed
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 2.5mg to 5.0mg daily | Aggressive protocol. Monitor hydration and kidney function extremely closely. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration 1: Low/Slow
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 1.0mg daily | Mitigates severe renal stress while providing steady adipose tissue apoptosis. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 250 mcg 1x Daily | Initiation phase. |
| Weeks 3-4 | 500 mcg 1x Daily | Escalation phase. |
| Weeks 5-6 | 750 mcg 1x Daily | Escalation phase. |
| Weeks 7-8 | 1000 mcg 1x Daily | Peak phase. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 3
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 330 mcg 1x Daily | Initiation phase. |
| Week 2 | 550 mcg 1x Daily | Escalation phase. |
| Weeks 3-4 | 1000 mcg 1x Daily | Peak phase. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (Prohibitin); route Subcutaneous; timing Anytime. Unapproved or unverified dosing examples are hypotheses, not recommendations. Adipotide is a high-caution fat-loss entry because the mechanism targets vasculature supplying fat tissue. That makes kidney, vascular, pregnancy, and cancer-context cautions more important than chasing aggressive fat-loss dosing.
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied mainly in obesity, type 2 diabetes, appetite regulation, cardiometabolic risk, and metabolic liver-disease settings depending on the molecule. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Prohibitin. Route(s): Subcutaneous. Dosing window on page: Anytime. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- Incretin and related appetite-hormone compounds should be evaluated through randomized trial endpoints, label dose escalation, cardiometabolic outcomes, and gastrointestinal tolerability.
- Class overlap matters: combining GLP-1, GIP, glucagon, or amylin agents can stack adverse effects without a validated efficacy benefit.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-4, 2.5mg to 5.0mg daily; Alternative Titration 1: Low/Slow: Weeks 1-6, 1.0mg daily.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor GI tolerance, hydration, glucose-lowering co-therapy, gallbladder/pancreatitis symptoms, pregnancy status, and weight-regain planning after discontinuation.
Selected medical sources
Independent evidence
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Pre-existing kidney disease, chronic kidney disease (CKD), or any impaired renal function: nephrotoxicity is the primary dose-limiting toxicity; even mild renal impairment is disqualifying.
- Concurrent use of nephrotoxic agents: aminoglycosides, NSAIDs, certain chemotherapy agents, IV contrast dyes, or any compound that stresses renal tubular function compound adipotide's off-target renal apoptosis.
- Concurrent use of anticoagulants: vascular disruption at adipose tissue sites increases bleeding risk; anticoagulation amplifies this.
- Concurrent use with AOD-9604: both compounds target adipose tissue through distinct mechanisms; combined use creates unpredictable systemic fat cell stress and additive risk.
- Active malignancy: vascular disruption agents may affect tumor vasculature unpredictably; the immune and inflammatory consequences of large-scale tissue destruction could promote tumor progression.
- Pregnancy: proapoptotic mechanism; no reproductive toxicology data exist; contraindicated absolutely.
- Breastfeeding: safety not established; avoid.
- Known hypersensitivity to adipotide or any formulation excipients.
- Conditions requiring intact adipose tissue signaling: white adipose tissue is an endocrine organ; subjects with conditions dependent on leptin, adiponectin, or other adipokine homeostasis may experience severe metabolic disruption from rapid adipose ablation.
- Severely underweight subjects or very low body fat: destruction of remaining adipose tissue may push subjects into ectopic fat deposition in organs (liver, muscle, pancreas) with paradoxically worse metabolic outcomes.
- Diabetes mellitus on insulin or glucose-lowering agents without dose adjustment: rapid weight-independent improvements in insulin sensitivity may cause hypoglycemia without medication adjustment.
- Pediatric use: safety and efficacy not established; absolutely contraindicated.
- Dehydration or inability to maintain adequate fluid intake during protocol: dehydration dramatically amplifies nephrotoxicity.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Renal tubular injury: primary and most serious adverse effect; dose-dependent nephrotoxicity observed consistently across all treated animals in primate studies; off-target prohibitin binding in renal tubular endothelium triggers same apoptotic cascade as in adipose vasculature.
- Elevated serum creatinine: direct marker of renal tubular injury; requires baseline labs and monitoring throughout cycle.
- Proteinuria: increased protein excretion in urine indicating glomerular or tubular compromise; monitor via urinalysis.
- Changes in urine output: decreased urine output may signal acute tubular injury; any sustained reduction warrants immediate cessation.
- Severe dehydration: adipose tissue apoptosis and subsequent inflammation drive significant fluid shifts; aggressive hydration is mandatory throughout the protocol.
- Excessive and potentially irreversible fat loss: the proapoptotic mechanism is not titrated precisely; subjects may lose more fat than intended, and destroyed adipose vasculature does not regenerate.
- Ectopic fat deposition risk: if adipose storage capacity is significantly reduced without corresponding dietary changes, excess calories may be deposited in the liver, skeletal muscle, or pancreas, paradoxically worsening metabolic health.
- Disrupted adipokine signaling: rapid destruction of white adipose tissue disrupts leptin, adiponectin, resistin, and other adipokine levels with unpredictable metabolic and appetite-regulating consequences.
- Secondary appetite suppression: observed in mouse studies; possibly mediated by disrupted leptin signaling as fat mass is rapidly depleted; may result in inadequate caloric intake.
- Rapid and unexpected improvements in insulin sensitivity: documented in primate studies independent of weight loss; may precipitate hypoglycemia in subjects on insulin or glucose-lowering agents.
- Immune activation and inflammatory response: large-scale adipose tissue cell death releases cellular debris requiring immune clearance; potential for systemic inflammatory response in high-dose protocols.
- Injection site reactions: localized inflammation at subcutaneous administration sites.
- Fatigue: systemic inflammatory load from concurrent tissue apoptosis and immune cleanup.
- No long-term human safety data exists: clinical development was discontinued; all safety information is derived from preclinical animal studies only.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.